Search results

15 results for Secukinumab

Sorted by Relevance . Sort by Date

  1. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

  2. Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

    Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults

  3. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional

  4. Psoriasis

    Everything NICE has said on psoriasis in an interactive flowchart

  5. Spondyloarthritis in over 16s: diagnosis and management (NG65)

    This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  6. Spondyloarthritis

    Everything NICE has said on diagnosing and managing spondyloarthritis in people aged 16 and over in an interactive flowchart

  7. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  8. Block scoping reports

    This information helps ministers to decide whether or not a technology should be formally referred to NICE for appraisal and whether it should be referred as an MTA or an STA.

  9. Musculoskeletal conditions

    Everything NICE has said on musculoskeletal conditions in an interactive flowchart